{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T03:48:33Z","timestamp":1770522513908,"version":"3.49.0"},"reference-count":0,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Exposing patients with metastatic colorectal cancer (MCRC) to all three active chemotherapeutic agents (oxaliplatin, irinotecan, fluorouracil) has improved survival. The benefit of second-line chemotherapy after a first-line triplet is not clearly defined. We evaluated the efficacy of second-line chemotherapy in patients who had received first-line triplet therapy. Methods: The medical records of patients treated on a prospective trial of first-line triplet therapy were reviewed for second-line treatment. Univariate and multivariate analyses were performed to establish factors of prognostic significance. Results: Of the 53 patients who received first-line triplet therapy, 28 (53%) received second-line chemotherapy [13 men; 8 with a colon primary; mutant KRAS in 10, wild-type in 15, and unknown status in 3; Eastern Cooperative Oncology Group performance status (PS) of 1 in 16 patients, PS 2 in 3, PS 3 in 2, and unknown in 7; involved organs: liver in 17 patients, lung in 16, and peritoneum in 8]. Second-line chemotherapy consisted of XELOX or FOLFOX in 13 patients, XELIRI or FOLFIRI in 12, and single-agent irinotecan in 3. Concurrent bevacizumab was given in 16 patients (57%), and cetuximab, in 2 (7%). Median survival was 28.0 months [95% confidence interval (CI): 22.8 months to 33.2 months] for patients receiving second-line therapy and 23.0 months (95% CI: 13.2 months to 32.8 months) for those not receiving it. Best response was partial in 6 patients (21%), stable disease in 11 (39%), and progressive disease in 11 (39%). Median progression-free survival was 4.8 months (95% CI: 2.4 months to 9.6 months), and overall survival was 15 months (95% CI: 9.6 months to 20.4 months). Conclusions: Second-line chemotherapy after first-line triplet therapy in MCRC is feasible and suggests efficacy comparable to that reported for second-line therapy after a doublet, regardless of the agent used.<\/jats:p>","DOI":"10.3747\/co.26.4217","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T18:47:21Z","timestamp":1551811641000},"page":"4217","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Second-Line Chemotherapy after a First-Line Triplet in Patients with Metastatic Colorectal Cancer"],"prefix":"10.3390","volume":"26","author":[{"given":"Shouki","family":"Bazarbashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Hakoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Gad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Elshenawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Aljubran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Eldali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,1]]},"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/current-oncology.com\/index.php\/oncology\/article\/viewFile\/4217\/3231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/current-oncology.com\/index.php\/oncology\/article\/viewFile\/4217\/3293","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/1718-7729\/26\/1\/4217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T13:22:26Z","timestamp":1613740946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/26\/1\/4217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["co.26.4217"],"URL":"https:\/\/doi.org\/10.3747\/co.26.4217","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}